People: China Grand Pharmaceutical and Healthcare Holdings Ltd (0512.HK)
Dr. Niu Zhanqi has been appointed as an Executive Director of the Company. He holds a bachelor’s degree in science from Nankai University and a doctoral degree (PhD) in pharmaceutics from Shenyang Pharmaceutical University. Dr. Niu has more than 10 years’ experience in pharmaceutical research and development. He is currently an executive president of the Pharmaceutical Management Headquarters of China Grand Enterprises Incorporation (“China Grand”), which is a company established in China -2- and is controlled and ultimately and beneficially owned by Mr. Hu Kaijun, a controlling shareholder (as defined in the Rules Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”)) of the Company. He has also been a director of Huadong Medicine Company Limited (“Huadong Medicine”), which is listed on the Shenzhen Stock Exchange (stock code: 000963), since June 2016. Huadong Medicine is owned as to approximately 41.77 % by China Grand as at the date of this announcement, and is therefore a connected person (as defined in the Listing Rules) of the Company.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|